MetaCap

Connect Biopharma (CNTB) vs Grace Therapeutics (GRCE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grace Therapeutics (GRCE) has outperformed Connect Biopharma (CNTB) over the past year, losing 46.4% versus a loss of 80.6%. Over five years, GRCE leads with a -79.3% price change compared with -86.9% for CNTB. Connect Biopharma is the larger company by market cap ($38.0 million vs $36.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTB-80.59%GRCE-46.39%
+68%-10%-88%
Nov 21, 20251 yearNov 20, 2026
CNTB-88.48%GRCE-80.48%
+5%-44%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTB versus GRCE key metrics
MetricCNTBGRCE
Share price$0.59$1.71
Market cap$38.05M$35.97M
1-day change-6.08%-0.58%
YTD return-79.08%-50.58%
1-year return-80.59%-46.39%
5-year return-86.89%-79.35%
EPS (TTM)$-1.14$-1.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$64.00K—
Revenue growth (YoY)-99.75%—
Net income (latest FY)$-55.48M$-7.79M
Operating margin-90740.63%—
Net margin-86687.50%—
52-week high$3.82$5.18
52-week low$0.55$1.64
Distance from 52-week high-84.55%-66.99%
Analyst consensusstrong_buynone
Avg. price target upside+896.61%+243.27%
Average volume3.98M119.27K
Shares outstanding64.49M21.04M
Employees645
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRCE has outperformed CNTB by 34.2 percentage points over the past year.

About Connect Biopharma

CNTB stock →

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).

Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees

About Grace Therapeutics

GRCE stock →

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CNTB vs GRCE FAQ

Which is bigger, Connect Biopharma or Grace Therapeutics?

Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $35.97M for Grace Therapeutics (GRCE).

Which stock has performed better over the past year, CNTB or GRCE?

GRCE returned -46.39% over the past 12 months, compared with -80.59% for CNTB (price return, excluding dividends). Past performance does not predict future results.

Are Connect Biopharma and Grace Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons